HepQuant Presents at Rocky Mountain Life Science Investor and Partnering Conference
HepQuant Presents at the 2017 Rocky Mountain Life Science Investor and Partnering Conference DENVER (October 12th, 2017) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced it presented at the 2017 Rocky Mountain…
HepQuant holding its 2017 Scientific Advisory Board Meeting in Washington D.C. on Saturday, October 21st
HepQuant to Hold 2017 Scientific Advisory Board October 21st in Washington, DC DENVER (August 31, 2017) — HepQuant, LLC, a diagnostics company, located in Greenwood Village, CO with unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced today announced it will be holding…
HepQuant to Sponsor its First Clinical Study
HepQuant to Sponsor its First Clinical Study Utilizing 3 Investigational Device Exemptions (IDEs) in Clinical Study of Patients with Alcoholic Hepatitis, NASH F3, NASH F4 DENVER (Sep. 28, 2017) — HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients…
HepQuant Announces Approval of 4th IDE
HepQuant Announces Approval of Fourth Investigational Device Exemption Application HepQuant SHUNT™ Liver Diagnostic Kit for use in a clinical study in subjects with Alcoholic Hepatitis DENVER (September 14, 2017) — HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with…
HepQuant Completes Third State-Sponsored Grant
HepQuant Completes Third State-Sponsored Grant State of Colorado funding enables advancement of supply chain, regulatory advancements and HepQuant laboratory DENVER (August 31, 2017) — HepQuant, LLC, a diagnostics company, located in Greenwood Village, CO with unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease,…
Test Inventor and Founder Dr. Everson Accepts Role as CEO
HepQuant Test Inventor and Founder Doctor Gregory T. Everson Accepts Position of CEO DENVER (July 1, 2017) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that its liver test inventor, Dr. Greg…